Loss of ARID1A expression correlates with stages of tumor progression in uterine endometrioid carcinoma

Tsui Lien Mao, Laura Ardighieri, Ayse Ayhan, Kuan Ting Kuo, Chen Hsuan Wu, Tian-Li Wang, Ie Ming Shih

Research output: Contribution to journalArticle

Abstract

ARID1A is a recently identified tumor suppressor that functions in chromatin remodeling. Inactivating mutations of ARID1A and loss of its expression most frequently occur in ovarian clear cell carcinoma, ovarian endometrioid carcinoma, and uterine endometrioid carcinoma. In this study, we performed a detailed immunostaining analysis of ARID1A in 246 cases including benign endometrium and endometrioid carcinoma at different stages of progression. Special attention was paid to recording intratumoral heterogeneity of clonal loss of ARID1A immunoreactivity. All normal endometria (n=51) and endometrial polyps (n=14) retained ARID1A expression. Among complex atypical hyperplasias (n=38), 16% exhibited clonal loss of ARID1A, but none showed complete loss. Among low-grade endometrioid carcinomas (n=88), 25% exhibited complete loss and 24% exhibited clonal loss. In contrast, 44% of high-grade endometrioid carcinomas (n=55) showed complete loss of ARID1A, and 9% exhibited clonal loss. We found that 19 high-grade carcinomas also contained concurrent low-grade carcinomas. In the high-grade areas, 63% exhibited complete loss and 11% exhibited clonal loss, whereas in the low-grade areas, 37% exhibited complete loss and 42% clonal loss. In 5 of these 19 cases, progressive loss of ARID1A from retention or clonal loss to complete loss was observed between the low-grade and high-grade areas. Overall, the percentage of complete ARID1A loss increased from 0% in complex atypical hyperplasia, to 25% in low-grade endometrioid carcinoma, to 44% in high-grade endometrioid carcinoma. These findings suggest that loss of ARID1A expression, presumably due to mutation, plays an important role in tumor progression of uterine endometrioid carcinoma.

Original languageEnglish (US)
Pages (from-to)1342-1348
Number of pages7
JournalAmerican Journal of Surgical Pathology
Volume37
Issue number9
DOIs
StatePublished - Sep 2013

Fingerprint

Endometrioid Carcinoma
Neoplasms
Endometrium
Carcinoma
Hyperplasia
Mutation
Chromatin Assembly and Disassembly
Polyps

Keywords

  • ARID1A
  • Endometrioid carcinoma
  • Gynecology pathology

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine
  • Surgery

Cite this

Loss of ARID1A expression correlates with stages of tumor progression in uterine endometrioid carcinoma. / Mao, Tsui Lien; Ardighieri, Laura; Ayhan, Ayse; Kuo, Kuan Ting; Wu, Chen Hsuan; Wang, Tian-Li; Shih, Ie Ming.

In: American Journal of Surgical Pathology, Vol. 37, No. 9, 09.2013, p. 1342-1348.

Research output: Contribution to journalArticle

Mao, Tsui Lien ; Ardighieri, Laura ; Ayhan, Ayse ; Kuo, Kuan Ting ; Wu, Chen Hsuan ; Wang, Tian-Li ; Shih, Ie Ming. / Loss of ARID1A expression correlates with stages of tumor progression in uterine endometrioid carcinoma. In: American Journal of Surgical Pathology. 2013 ; Vol. 37, No. 9. pp. 1342-1348.
@article{7cb5387cc9a84548a086208e3964b768,
title = "Loss of ARID1A expression correlates with stages of tumor progression in uterine endometrioid carcinoma",
abstract = "ARID1A is a recently identified tumor suppressor that functions in chromatin remodeling. Inactivating mutations of ARID1A and loss of its expression most frequently occur in ovarian clear cell carcinoma, ovarian endometrioid carcinoma, and uterine endometrioid carcinoma. In this study, we performed a detailed immunostaining analysis of ARID1A in 246 cases including benign endometrium and endometrioid carcinoma at different stages of progression. Special attention was paid to recording intratumoral heterogeneity of clonal loss of ARID1A immunoreactivity. All normal endometria (n=51) and endometrial polyps (n=14) retained ARID1A expression. Among complex atypical hyperplasias (n=38), 16{\%} exhibited clonal loss of ARID1A, but none showed complete loss. Among low-grade endometrioid carcinomas (n=88), 25{\%} exhibited complete loss and 24{\%} exhibited clonal loss. In contrast, 44{\%} of high-grade endometrioid carcinomas (n=55) showed complete loss of ARID1A, and 9{\%} exhibited clonal loss. We found that 19 high-grade carcinomas also contained concurrent low-grade carcinomas. In the high-grade areas, 63{\%} exhibited complete loss and 11{\%} exhibited clonal loss, whereas in the low-grade areas, 37{\%} exhibited complete loss and 42{\%} clonal loss. In 5 of these 19 cases, progressive loss of ARID1A from retention or clonal loss to complete loss was observed between the low-grade and high-grade areas. Overall, the percentage of complete ARID1A loss increased from 0{\%} in complex atypical hyperplasia, to 25{\%} in low-grade endometrioid carcinoma, to 44{\%} in high-grade endometrioid carcinoma. These findings suggest that loss of ARID1A expression, presumably due to mutation, plays an important role in tumor progression of uterine endometrioid carcinoma.",
keywords = "ARID1A, Endometrioid carcinoma, Gynecology pathology",
author = "Mao, {Tsui Lien} and Laura Ardighieri and Ayse Ayhan and Kuo, {Kuan Ting} and Wu, {Chen Hsuan} and Tian-Li Wang and Shih, {Ie Ming}",
year = "2013",
month = "9",
doi = "10.1097/PAS.0b013e3182889dc3",
language = "English (US)",
volume = "37",
pages = "1342--1348",
journal = "American Journal of Surgical Pathology",
issn = "0147-5185",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Loss of ARID1A expression correlates with stages of tumor progression in uterine endometrioid carcinoma

AU - Mao, Tsui Lien

AU - Ardighieri, Laura

AU - Ayhan, Ayse

AU - Kuo, Kuan Ting

AU - Wu, Chen Hsuan

AU - Wang, Tian-Li

AU - Shih, Ie Ming

PY - 2013/9

Y1 - 2013/9

N2 - ARID1A is a recently identified tumor suppressor that functions in chromatin remodeling. Inactivating mutations of ARID1A and loss of its expression most frequently occur in ovarian clear cell carcinoma, ovarian endometrioid carcinoma, and uterine endometrioid carcinoma. In this study, we performed a detailed immunostaining analysis of ARID1A in 246 cases including benign endometrium and endometrioid carcinoma at different stages of progression. Special attention was paid to recording intratumoral heterogeneity of clonal loss of ARID1A immunoreactivity. All normal endometria (n=51) and endometrial polyps (n=14) retained ARID1A expression. Among complex atypical hyperplasias (n=38), 16% exhibited clonal loss of ARID1A, but none showed complete loss. Among low-grade endometrioid carcinomas (n=88), 25% exhibited complete loss and 24% exhibited clonal loss. In contrast, 44% of high-grade endometrioid carcinomas (n=55) showed complete loss of ARID1A, and 9% exhibited clonal loss. We found that 19 high-grade carcinomas also contained concurrent low-grade carcinomas. In the high-grade areas, 63% exhibited complete loss and 11% exhibited clonal loss, whereas in the low-grade areas, 37% exhibited complete loss and 42% clonal loss. In 5 of these 19 cases, progressive loss of ARID1A from retention or clonal loss to complete loss was observed between the low-grade and high-grade areas. Overall, the percentage of complete ARID1A loss increased from 0% in complex atypical hyperplasia, to 25% in low-grade endometrioid carcinoma, to 44% in high-grade endometrioid carcinoma. These findings suggest that loss of ARID1A expression, presumably due to mutation, plays an important role in tumor progression of uterine endometrioid carcinoma.

AB - ARID1A is a recently identified tumor suppressor that functions in chromatin remodeling. Inactivating mutations of ARID1A and loss of its expression most frequently occur in ovarian clear cell carcinoma, ovarian endometrioid carcinoma, and uterine endometrioid carcinoma. In this study, we performed a detailed immunostaining analysis of ARID1A in 246 cases including benign endometrium and endometrioid carcinoma at different stages of progression. Special attention was paid to recording intratumoral heterogeneity of clonal loss of ARID1A immunoreactivity. All normal endometria (n=51) and endometrial polyps (n=14) retained ARID1A expression. Among complex atypical hyperplasias (n=38), 16% exhibited clonal loss of ARID1A, but none showed complete loss. Among low-grade endometrioid carcinomas (n=88), 25% exhibited complete loss and 24% exhibited clonal loss. In contrast, 44% of high-grade endometrioid carcinomas (n=55) showed complete loss of ARID1A, and 9% exhibited clonal loss. We found that 19 high-grade carcinomas also contained concurrent low-grade carcinomas. In the high-grade areas, 63% exhibited complete loss and 11% exhibited clonal loss, whereas in the low-grade areas, 37% exhibited complete loss and 42% clonal loss. In 5 of these 19 cases, progressive loss of ARID1A from retention or clonal loss to complete loss was observed between the low-grade and high-grade areas. Overall, the percentage of complete ARID1A loss increased from 0% in complex atypical hyperplasia, to 25% in low-grade endometrioid carcinoma, to 44% in high-grade endometrioid carcinoma. These findings suggest that loss of ARID1A expression, presumably due to mutation, plays an important role in tumor progression of uterine endometrioid carcinoma.

KW - ARID1A

KW - Endometrioid carcinoma

KW - Gynecology pathology

UR - http://www.scopus.com/inward/record.url?scp=84884507473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884507473&partnerID=8YFLogxK

U2 - 10.1097/PAS.0b013e3182889dc3

DO - 10.1097/PAS.0b013e3182889dc3

M3 - Article

VL - 37

SP - 1342

EP - 1348

JO - American Journal of Surgical Pathology

JF - American Journal of Surgical Pathology

SN - 0147-5185

IS - 9

ER -